Long-term liver transplant outcomes for progressive familial intrahepatic cholestasis type 1: The Pittsburgh experience.

Abstract

Progressive familial intrahepatic cholestasis type 1 (PFIC1) arises from biallelic variants in the ATP8B1gene that annul FIC1 activity, resulting in progressive liver disease. Liver transplant (LT) is indicated in refractory disease; however, post-LT complications including worsening diarrhea and steatohepatitis progressing to fibrosis with graft loss have been reported. We aim to describe long-term outcomes of PFIC1 LT recipients at our center, focusing on the histological changes of the allografts. We assessed 7 PFIC1 patients post-LT at the Children's Hospital of Pittsburgh (CHP). All pre-transplant, explant, and sequential post-transplant pathology samples were reviewed. Continuous data are presented as the mean±SD. We compared the pre- and post-transplant height and weight z-scores using Wilcoxon signed-rank test. Seven (29% male) patients with PFIC1 received a LT (n=6) or had post-LT care (n=1) at CHP. Six had confirmed or suspected identical genetic. At a mean follow-up of 10.9years, both patient survival and graft survival were 100%. Diarrhea persisted (n=3) or newly developed (n=4) in all patients after LT contributing to ongoing growth failure, with mean z-scores -2.63 (weight) and -2.98 (height) at follow-up. Histologically, allograft steatosis was common but was not accompanied by significant inflammation, ballooning, or fibrosis. We show that extrahepatic disease persists and near-universal allograft steatosis occurs. However, at a mean follow-up period of over 10years, no patients developed steatohepatitis or significant fibrosis, and both patient survival and graft survival are excellent.